{"ticker": {"uuid": "85cf1839-5d87-4b1b-8118-600d01682cf0", "symbol": "VRTX", "name": "Vertex Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating Crinetics Pharmaceuticals (CRNX), Twin Vee PowerCats Co. (VEEE), NextCure, Inc. (NXTC), and TriCo Bancshares (TCBK) for potential violations of federal securities laws and breaches of fiduciary duties related to thei", "url": "https://www.tradingview.com/news/prnewswire:43c3b3245fb28:0-are-crnx-veee-nxtc-tcbk-obtaining-fair-deals-for-their-shareholders/", "source_name": "TradingView", "published_at": "2026-07-21T19:11:15", "published_display": "21 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxPaDJTZGVSckVJSG5IU1lXSTUxTUdVZlljZmVpdlEwV3R5akVqdmZmU044Z1M4UEJDM3Y5em5VcGJ1eGhvamxDWnktcnQ2eXRBbDhPdHJocU9xbEwyZjRfYnJaYlVTZ0ZvemxXSURYbFRWWldMb2RWYndOXzlxX2p2Y21YaEpuMXJjbUZSY2pqVDctVTloWlU5cDhVb3RiTEwzTVhnS25mZGhrUElzVXNwMk5GbDI1T2tpVFBYRjFqbTF3Rk9nNU1fLUp6TEJhMERWQ1dHVWtJZTRtNkdXd1dPSVJWYTRMOUhYX3Itd0dlUTNqVC1CWWRpNDV5S1o?oc=5", "source_name": "ChartMill", "published_at": "2026-07-21T12:20:29+00:00", "published_display": "21 Jul 2026 12:20", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19", "summary": "Morgan Stanley has downgraded Vertex Pharmaceuticals (VRTX) from \"Overweight\" to \"Equalweight\" and significantly reduced its price target from $19 to $15. This adjustment reflects a more cautious outlook from the investment bank regarding the pharmaceutical company's future perfo", "url": "https://www.marketscreener.com/news/morgan-stanley-downgrades-vertex-pharmaceuticals-to-equalweight-from-overweight-adjusts-pt-to-15-f-ce7f51dbd08bf020", "source_name": "marketscreener.com", "published_at": "2026-07-21T09:39:19", "published_display": "21 Jul 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Stock Trades Below Fair Value After Deal Plans", "summary": "Vertex Pharmaceuticals (VRTX) stock is currently trading below its estimated intrinsic value, according to a Discounted Cash Flow (DCF) model, despite a mixed picture from broader valuation checks and an upcoming $10 billion acquisition of Crinetics Pharmaceuticals. While the DCF", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-pharmaceuticals-vrtx-stock-trades-below-fair-value-af", "source_name": "Simply Wall Street", "published_at": "2026-07-21T01:09:00", "published_display": "21 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today", "summary": "Vertex Pharmaceuticals (VRTX) shares dropped by 1.06% to $480.50, underperforming the broader S&P 500, Dow, and Nasdaq markets. Despite this daily dip, the drugmaker has seen a 7.53% appreciation over the past month, outperforming its sector and the S&P 500. Investors are now loo", "url": "https://finance.yahoo.com/markets/stocks/articles/why-vertex-pharmaceuticals-vrtx-dipped-220006350.html", "source_name": "Market source", "published_at": "2026-07-20T21:38:55", "published_display": "20 Jul 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors", "summary": "Shares of Vertex Pharmaceuticals Inc. (VRTX) fell 1.06% on Monday, closing at $480.50. This underperformance occurred during a generally poor trading session where the S&P 500 Index declined by 0.19% and the Dow Jones Industrial Average dropped by 0.59%. This marks the second con", "url": "https://www.marketwatch.com/data-news/vertex-pharmaceuticals-inc-stock-underperforms-monday-when-compared-to-competitors-dbeedc00-cf7aec63ddb5", "source_name": "MarketWatch", "published_at": "2026-07-20T16:37:00", "published_display": "20 Jul 2026 16:37", "sentiment": "negative", "sentiment_pct": 27, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharma stock trades near highs as cystic fibrosis portfolio drives double digit revenue growt", "summary": "Vertex Pharmaceuticals (Vertex Pharma) stock is trading near highs due to robust revenue and profit growth driven by its cystic fibrosis (CF) portfolio. The company reported double-digit revenue increases and strong operating margins in its latest quarter, primarily from its CF t", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/vertex-pharma-stock-trades-near-highs-as-cystic-fibrosis-portfolio-drives/69813959", "source_name": "ad-hoc-news.de", "published_at": "2026-07-20T14:14:44", "published_display": "20 Jul 2026 14:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating", "summary": "Goldman Sachs has increased its price target for Vertex Pharmaceuticals to $652 from $641. The firm has concurrently maintained a \"Buy\" rating on the stock. This adjustment reflects Goldman Sachs' continued positive outlook on Vertex Pharmaceuticals.", "url": "https://www.marketscreener.com/news/goldman-sachs-adjusts-price-target-on-vertex-pharmaceuticals-to-652-from-641-maintains-buy-rating-ce7f51dbdb88f52c", "source_name": "www.marketscreener.com", "published_at": "2026-07-20T12:03:00", "published_display": "20 Jul 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex\u2019s IgA nephropathy drug derisked after Novartis, Vera approvals", "summary": "Vertex Pharmaceuticals' IgA nephropathy drug, povetacicept, is gaining momentum following recent FDA approvals for competing therapies from Novartis (Fabhalta) and Vera Therapeutics (Trutakna). Analysts believe these approvals will help educate the market and create a positive en", "url": "https://www.biospace.com/drug-development/vertexs-iga-nephropathy-drug-derisked-after-novartis-vera-approvals", "source_name": "BioSpace", "published_at": "2026-07-20T11:31:10", "published_display": "20 Jul 2026 11:31", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exploring High Growth Tech Stocks In The US For July 2026", "summary": "This article identifies top-performing high-growth tech stocks in the US for July 2026, amidst a market that has seen a 17% increase over the past year. It highlights companies like Travere Therapeutics, Madrigal Pharmaceuticals, and Cloudflare, detailing their operational focus,", "url": "https://simplywall.st/stocks/us/software/nyse-net/cloudflare/news/exploring-high-growth-tech-stocks-in-the-us-for-july-2026", "source_name": "Simply Wall Street", "published_at": "2026-07-20T10:41:07", "published_display": "20 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Stock Analysis: A Healthcare Giant with 14% Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPMmVxbEVMV2R1N1lRaHRuMDZYcnczcFdHc183ME1GUGpzd041ektydEpyaF93NDBqMGV3VlR0dzBBd3puVlpMenEtWWRmTTUyTWJGNDhJaVItQjB2LVB2alJFcUpCUXBTUFVyMzhUdlJ1WHBKRGVmcml0QnMtbVI2LXBoeTkwMXhTYXg4X1R4ZTFVTE12U0NxUnJVNlZHMmtLeC14aDh1eFFTOW5WWUpENGFqSDBjc0hOUFpHbmgtYzdhdV9EMXh0U1RZY0w3UERqN2JJ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-20T09:22:21+00:00", "published_display": "20 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How FDA\u2019s Pediatric Expansion of Casgevy at Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/fda-pediatric-expansion-casgevy-vertex-090930514.html", "source_name": "Simply Wall St.", "published_at": "2026-07-20T09:09:30+00:00", "published_display": "20 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals (CRNX) Proxy filing Summary", "summary": "Vertex Pharmaceuticals is set to acquire Crinetics Pharmaceuticals for approximately $10 billion ($8.8 billion net of cash), paying $85 per share in cash. This acquisition will bring PALSONIFY and atumelnant into Vertex's portfolio, with an expected combined peak annual revenue p", "url": "https://quartr.com/events/crinetics-pharmaceuticals-inc-crnx-proxy-filing_FkTiKVDo", "source_name": "Quartr", "published_at": "2026-07-20T09:41:34", "published_display": "20 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2", "summary": "Vertex Pharmaceuticals' gene therapy, exagamglogene autotemcel (Casgevy), has received expanded FDA approval to treat children as young as 2 years old with sickle cell disease or transfusion-dependent thalassemia. This approval provides new options for a pediatric group with limi", "url": "https://sg.finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-wins-fda-050717227.html", "source_name": "Market source", "published_at": "2026-07-20T05:07:21", "published_display": "20 Jul 2026 05:07", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching", "summary": "Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals for $10 billion to diversify its portfolio beyond its dominant cystic fibrosis drug market. The acquisition introduces Palsonify for acromegaly and pipeline candidates like atumelnant for congenital adrenal hyperp", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VRTX/pressreleases/3357249/vertex-pharmaceuticals-just-made-a-10-billion-acquisition-worth-watching/", "source_name": "The Globe and Mail", "published_at": "2026-07-19T22:08:56", "published_display": "19 Jul 2026 22:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Latigo preps IPO to fund non-opioid pain drug rival to Vertex\u2019s Journax", "summary": "Latigo Biotherapeutics plans an IPO to fund its non-opioid pain drug pipeline, including late-stage studies for LTG-001, an oral small-molecule Nav1.8 inhibitor. The company aims to compete with Vertex Pharmaceuticals' Journax, highlighting potential advantages in efficacy and ad", "url": "https://www.fiercebiotech.com/biotech/latigo-preps-ipo-fund-non-opioid-pain-drug-rival-vertexs-journax", "source_name": "Fierce Biotech", "published_at": "2026-07-19T14:07:00", "published_display": "19 Jul 2026 14:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?", "summary": "Penguin Solutions (PENG), Arista Networks (ANET), and Biocryst Pharmaceuticals (BCRX) all reached 52-week highs due to positive market sentiment and various catalysts. PENG benefited from increased analyst price targets driven by AI demand, ANET saw optimism for its cloud network", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-peng-anet-bcrx-shares-surge-to-52-week-highs/cZmokfgR7VS", "source_name": "Stocktwits", "published_at": "2026-07-18T15:40:03", "published_display": "18 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Arrowhead Pharmaceuticals (ARWR) Undervalued Or Is Its Pipeline Promise Already Priced In?", "summary": "Arrowhead Pharmaceuticals (ARWR) has seen recent stock volatility, with a 4.1% gain in the past day but an 8.3% drop over the last month, yet a strong 1-year return. Analysts view the stock as undervalued with a fair value of $89.08 against its current $74.30, driven by its promi", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/is-arrowhead-pharmaceuticals-arwr-undervalued-or-is-its-pipe", "source_name": "Simply Wall Street", "published_at": "2026-07-18T11:41:14", "published_display": "18 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Pediatric Casgevy Expansion and Canadian ALYFTREK Talks Change Vertex Pharmaceuticals' (VRTX) Narrative?", "summary": "U.S. regulators recently expanded approval of Vertex Pharmaceuticals' gene-editing therapy Casgevy for pediatric patients as young as 2 years old. Concurrently, Canada's pan-Canadian Pharmaceutical Alliance has initiated discussions for public reimbursement of Vertex's cystic fib", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/will-pediatric-casgevy-expansion-and-canadian-alyftrek-talks", "source_name": "Simply Wall Street", "published_at": "2026-07-18T03:47:39", "published_display": "18 Jul 2026 03:47", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Catalyst Pharmaceuticals (CPRX) Keep Looking Fairly Valued Now?", "summary": "Catalyst Pharmaceuticals stock has seen a significant 4.6x return over the past five years, yet its current valuation appears to be roughly in line with its fundamentals rather than being clearly cheap or overvalued. The company's P/E ratio of 17.4x is close to its estimated fair", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/can-catalyst-pharmaceuticals-cprx-keep-looking-fairly-valued", "source_name": "Simply Wall Street", "published_at": "2026-07-18T01:39:28", "published_display": "18 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monteverde investigates Element Solutions, Crinetics, and AstroNova sales", "summary": "Monteverde & Associates PC is investigating the proposed sale of Element Solutions Inc to Solstice Advanced Materials Inc for potential undervaluation and process adequacy. The firm is also scrutinizing the acquisitions of Crinetics Pharmaceuticals by Vertex Pharmaceuticals and A", "url": "https://scanx.trade/stock-market-news/companies/brodsky-smith-probes-four-mergers-over-potential-board-breaches/44910462", "source_name": "scanx.trade", "published_at": "2026-07-17T22:40:14", "published_display": "17 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains", "summary": "Shares of Vertex Pharmaceuticals Inc. (VRTX) rose 1.88% on Thursday, closing at $486.03. Despite this gain, the stock underperformed the broader market, with the S&P 500 Index falling 0.51% and the Dow Jones Industrial Average dropping 0.20%. This marks the second consecutive day", "url": "https://www.marketwatch.com/data-news/vertex-pharmaceuticals-inc-stock-underperforms-thursday-when-compared-to-competitors-despite-daily-gains-19a02af6-ea4f441256e3", "source_name": "MarketWatch", "published_at": "2026-07-16T16:36:00", "published_display": "16 Jul 2026 16:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOSDV4a01ZcnR5VndFbmVYc0t5clpyeTFZRzk1cG5hdDV2VEFyMjJRQkN6cGlKNWEyWjhwb2F5SVhpU2NYMjYxZnFUZGhWSW1JM2JyQ1YwT2dNTmFpVzlaWXlpRDRuQzlqVExlVzZtWC1DSVJXUDhSUFMyaVdVTXRNcy1Kd3QtNHdoNWhobXh5WVNYc3hpWDY4RmZfaTlleURIYUJyVkhfVV9KZ1VJZjFCTmc3YVM?oc=5", "source_name": "Market source", "published_at": "2026-07-16T13:00:03+00:00", "published_display": "16 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex (VRTX) Is Buying Crinetics For $10 Billion To Enter Adrenal Disease", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T12:51:43+00:00", "published_display": "15 Jul 2026 12:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vertex Pharmaceuticals (VRTX) A Bargain On Its Expanded CASGEVY Approval?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-14T01:02:21+00:00", "published_display": "14 Jul 2026 01:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vertex (VRTX) Stock May Be 36% Undervalued Following Its $10b Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNTk9HVDlSOUNLT1UtdHJneGNsa0JNaURYMFBZSDFTMGJlV19vb2NlUzcwTzFUbHIxMWhhdUhqSUs0b2prdUdTUTdGZ3hUQkt4Y09hMC1DMHVGMENIX1E4MVFMUjVSUllMOVJQRUtQdTM1ejZJNldGVkhaRjRsQVR4dWRodGJkM09xNzk2WmVrZ3h3ZXc?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex to buy Crinetics for $10 billion in rare-diseases push", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOX3N1NDFzcDNMSmVSODY1SEJGRm51Sl96QmtwWV9zMHA3RUZTRVlDenhJaG01alZQSU5KZUNWV2NFMFp6c0U5Xy1aZFZ2UXVmNWFGNk1HR1NMcGpJWHVpQjVtQWV2Z0FqMldWWHFwMlA2cHh1eDBtT19sem9BZ1ljblQta09WbWdBcjFzX3JVY2h2WlFsQ1VZ?oc=5", "source_name": "Reuters", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech (VRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPeUVTekQtYjFqODVQTUpmWnpTSlBZT3lEWmhDVjhFZEc2dDctNjZXZ0MySENpa01tQS1CLVgtNTB6cGRWNWIyME9BOGhpRGlDYWF2bWYxRHlnbEtmN3FuZUlVT2c5NVhqZlNjSUlVTWxvYUFCX29xUU4wemRLYkhnOFhnOFhBVmJvYVk5Q1VfaW5KLWN0bElGRG9fdmlXZ1VpNjRqR3NTaWlqQVRCOHdLRkUzdTlLblNPOENJ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOYUJCRHpLdzhuNmcxVnZLVUVLSWc3U0JqNVpuOHNLbmMwZmE4NG1Yb2M3Xy1CMUk0T1hjM3VmeEpTV2xJMmVTX1BiMk5VOG93WS1TeG1fQ2NlYk44cHBfQzFTZ2U1UERQSHlYU2lDeG1SQzNMOVJyazRvSDdVZ0JuMUtMbGdSU2xVXzBuRjdDN2dwaUd5Y1pXdVQwZ3h2alFHb0k3ZE9CVUM?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Stock After Strong Multi\u2011Year Run Is The Price Still Reasonable", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNVW9halB2RDE0V056SmV5NEd0Wl95ekI0eWM3QzVsckpLQ2RMWkF3SWRMSUFmMlViUHBObGVobXhwYW5CWU42WG5NUG45WHhDNGEzcHlheG1hM1lZWkpTOUs3UFFmUHdDOUw2V2tEV0N4YnlMY0d0cmswalo4WnZzTWlVZGd6ZmdyeW5WSXZJRFplSFkyRnREQnlJaVN4MFA3WS1uWU55blg?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Pediatric CASGEVY Data Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPNzJydi1RUXhvaVExQVVJWnhpYjEyb3NOVHJheExOYmsyLU5famxjRnRWdS1TSDJLWjZNUmtEa3RLNkZxaGVtYWNPSmFLSFJnNktJWDVHSk9DVFlmVVdLLWRmWHdiR19LZXpWZm9MWlU4VkVOOGp0QktVX3ZmdWtiZ25BSS05SzVqaEtacm9fSGI4bzcyMVN0RTNIWWFCaTA?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQY2F4dS1iZUJuTE1VNlVHQ1paVHg1U2VRUG5vcTZFdmFSdXB0Z0RQdVlkUXdxNzhYaGIzOVNhVWctVnJpUG1ZZFNydFkwUGo4Si1UdmtSaFNXb1RuQnNFdU1vekFEU3pGYVhwUnlvY01zdmJ6dXZrZ1Bia3ZDRHI4NGRCN1ZudnRWMkVYMzhleWp5OHpmdjJOdkRhVDJKYW9VMXE1dDV6dVhJQzR4aXI4?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQRWxFWWN4YWJiVXFtSzNneEtya1lidllZZmNGU3o3UUZMYU9nQUs1aEhsU1Vtc3I0ejVrLUladllOb2dGOS1WdUEwa3poZW42M0dsOHI0dVdpVUMxZW5tTTY3UWR3NEdNLUxUcEpVTVdtOVRtMDJudHZWQVFrNTBHRU9JSlB5WEJjUUZFRHZtU29CUVc1d1lnaWFGakRvdVRmMmZXWU1STlNOaXp4M1FmR1JoTlFQdVdfbWZFLVBsODM0ZVNVbF9sUjgzQkhscWRMQ2QwanU2UVhEazNOQmp6Y1VlYW0?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vertex Pharmaceuticals (VRTX) Offering An Opportunity After Recent Share Price Consolidation?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPcWMwYWZZaUg0UXcyV2UzR2RLeWJQYVZLWmJBakdUSDJQWWh3aUZaR3BpbVAzR1c2eDRmSzBoR0FJQjlfNVhYZjdmMTNxUm81OXJwaGhza1lYRm1OVXZHMDd1LUUwSDBzNzQzREwyWDAtenRZQVRBR1ZsT1FXbXhxWmxXWHU5SDZ1SlNTdFpBUXJNclVGSXBRMUpJc0lvRFNNemw2TnJ1aVlUYk01VHhFVThEaw?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vertex Pharmaceuticals (VRTX) Offering Opportunity After Recent Pipeline Headlines And DCF Valuation Gap", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPS0tESHdtOGhOSUhoZ3VTUUtOSXY0S3hLNzdNYmZMcmpMSTJVQkNpZDk2RzJDTEJJckdoNFZkR29zVGI3Vmh5OFV5cU5QNV80MFc1cjhyTlhKcFB2UG9MbkRoR2xZamR1NkNBQmhsRFRDYkQ1U21jLWpoMWE3bmxxT3BOY05vdjhWWmF0UXNGdjEyZE9TcjJYTlpfMnJOa2sxalJPT21rYWQ2d1JwZ0ZDa3pR?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vertex Pharmaceuticals Stock Analysis: 1991 IPO Growth and 2026 Outlook - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPWDdRcmJnTUNiVGhhT0JTbEFuUzBQMm1JMmdoeFMxdld2TzM2LU8zZ2U4TWY5R0NRV2ZhX3dOT0pOS1JxekZwSERNZ1B2cDNkSFBNQUtBVVdhZVd0VHkxa1dpQlo0WTVNbXh5VXBWal9jOUdjZDVOQXg1N1UwdGN5LW14Q2YxLTZxR2xlVFA2SGpvOHRVWjlpNm5VTEZHZw?oc=5", "source_name": "IndexBox", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Profitability Return Tests Bullish Narratives Ahead Of Q1 2026 Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNRWFOTVJScjVfeFpiVTZmc2hTeXlYcGZrcTQzOVJ4Zm56Q3R0TUZNekFxT2ctOG90ZEJVRng5OVFaZ2JFQmNaaXBLazVPZTNaNDUxS0JhdEotYXlYMTR5aC1ocFo4REoxeVBkOUU1bEF3Q2tuSkxvYUh0aUxwSWh0ZlFfdkcwMHlNNUNxRGE0dVMzd1lfRC14TFppTzNaU3BtWk03Tl9hZ1Q1VEVt?oc=5", "source_name": "Business Wire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNbVlsb21NeHAzaFNyd2hzWmpjT3FkXzc1STMxN1pXelBvT0NqOEk3bnVybk1pUU4tTTZBc3M5eDdhaHNvUGp2MHZRNVc1S043NTVQc19kak5naTFENW5IMDhJYTlqZWdhRm1KMmhVbkFtVjh6bGc5dWhVVkR2UEZ6TENsZWFrNngyOHA4RjdHSW5JQjh4S3lXcjQ5UDhXZ0dWeW5UWHJtN3QyR1FHdU1WMWZFdGllZHVUQ2JtVGpoZmZXN0dQX0tsYXlETTREX2xLQ2hxTS1GREZkY1BfdEhlVFZ3YVJYOEItZmVkUm0xOVg?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vertex Pharmaceuticals Stock Looks Undervalued in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNWTUyZHZlVTI5dzItanJQSzJuOG15WjgyYWhfeGM0d2Q0S0FjRG9MYWdYaTZrbndwUG95T3hCVklReU5hQnlTc3VoWF9BM1h5WUhoendEeVdXaGxnc2Zpc0pEd0lwWVM3bFFMS0ROSE8yT0d0UHYxbV9vNzk1Y05mc2FfNy16Q1l2aWZzOQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPNWgxZmFPcUY5cHVqUjNNZ2pHVDE5Y0FJdnZBYmxLQlBKZnlGMC10UExaNUdzc0U1cWQxbmVKa1gzekFIazRWN3RsTTFKTGU0bURmV0dSbFVvVllDQS1mNnprR3lGQUxEQnNLR1FPWWhVdDZOVE9fRWZ4THNNQzdoUnk3ajg4amROUE9oUXBzWDFRUjg5N3c5ZzZ4S1NoeEkyNFY1OWVkQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQR3pDcWtZWjd1c1dwOTlpY0cwZUJkYWJCLVBlS0o0Y0ctOE5ENUh5b2dicHhSdGxmR19XblF0UzgtQkVaOTM1ZnFGcl85bS1DMGYtRzI5bTZwMVByeWs5YmVYcVR5elM4cjVHVmQ3aHpHWlRScUFKRWxtUVl3c3lhcFpndWt5MlVJY0xpdUpiRkNsUk84U3kyVHZLT2tPT3F5am40bE9YWFA?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals: Label Expansions For ALYFTREK & TRIKAFTA Plus Strong Demand (VRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPUG5ldEEyRWNlMlBnYTQyU0NlOHJScURVaWh2QzlncFdHRk1mQnlJRmZWUXNBa1EyVldJNXNCc3RxUVdzWXQ2eGllVnRVOG5PUHFhZm8tZUhEWmotYU9TX0lKYmJGd3ZuVTdoaGZWRmVVNXJPME5JYk1qR19od2JmY1NnZzM1aDFJNERPd01EUkt0YTB2YUt1YnpHT1lkZ21uZVhYd0laZDZlelpQbGI0bi1KSmFFU1JHSzg5NA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 80, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPdXIxTVd1ZHVTWmF3Tk55OHVsWW1aa204VXlzNkZuQWpfaGJkRjhlRncxRkZUb2ctYlJLV1hiY0QxYlFzMW9OS1A1WjlzaDhrclNGZUtXZ1gyRVNaTDRkUi1PcjBnVTBiVnpFaGdQWVBDRjh6b2FNZVNHcndESkNydFByQWVVTE9yU2RoUnZMSTFVdGdNakt0TlpoNXg5SnRDaWZSMUprbw?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Stocks making the biggest moves midday: Rivian, Hims & Hers, BioNTech, Vertex Pharmaceuticals & more", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxORWx1NTliZE5Gbm9JQTc5eWNBTDdjUWI3UEZtenJzM3g4aHJfVDF3cEtQNkdFQUpXQ2pWNW9qTkkxVFVjaVJPS0ZkbkptSmFrT2ZDQlktRE5UZG8ycGRpSl9nZ1JtY19fY1BTeDBGbXliS1RWVVdfUVNFaXpLVjdrT2s2dW5JNi1ZcjVSQ3lfMnVnekQzWE03dHZLbW9uQ1hX?oc=5", "source_name": "CNBC", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals Stock Pops 5% On Successful Late Stage Kidney Disease Drug Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxON3huRVNtLUZSdmZJR3AzZ1BJNlZfV3haaFBfRy1YMXFiYzV3NElYWlZyMHpqTXpSWTBXWGtfSHEzM0pkYWZpRWdqSENTeXA2RnhzZ3RGb1BuR1poVHV2Q3VyZ2lFN1ZZTC1MM0w3S2VQZ2tudllsYUpwQjBhcFMtbGhFT0tZaUtsSmF5QzY3RkNuMkFRZ3Z4dGEzVjVVU2tlNl9zNk41V2toQXlSQmlONnZOYmNRWWRY?oc=5", "source_name": "TIKR.com", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating Crinetics Pharmaceuticals (CRNX), Twin Vee PowerCats Co. (VEEE), NextCure, Inc. (NXTC), and TriCo Bancshares (TCBK) for potential violations of federal securities laws and breaches of fiduciary duties related to thei", "url": "https://www.tradingview.com/news/prnewswire:43c3b3245fb28:0-are-crnx-veee-nxtc-tcbk-obtaining-fair-deals-for-their-shareholders/", "source_name": "TradingView", "published_at": "2026-07-21T19:11:15", "published_display": "21 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxPaDJTZGVSckVJSG5IU1lXSTUxTUdVZlljZmVpdlEwV3R5akVqdmZmU044Z1M4UEJDM3Y5em5VcGJ1eGhvamxDWnktcnQ2eXRBbDhPdHJocU9xbEwyZjRfYnJaYlVTZ0ZvemxXSURYbFRWWldMb2RWYndOXzlxX2p2Y21YaEpuMXJjbUZSY2pqVDctVTloWlU5cDhVb3RiTEwzTVhnS25mZGhrUElzVXNwMk5GbDI1T2tpVFBYRjFqbTF3Rk9nNU1fLUp6TEJhMERWQ1dHVWtJZTRtNkdXd1dPSVJWYTRMOUhYX3Itd0dlUTNqVC1CWWRpNDV5S1o?oc=5", "source_name": "ChartMill", "published_at": "2026-07-21T12:20:29+00:00", "published_display": "21 Jul 2026 12:20", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19", "summary": "Morgan Stanley has downgraded Vertex Pharmaceuticals (VRTX) from \"Overweight\" to \"Equalweight\" and significantly reduced its price target from $19 to $15. This adjustment reflects a more cautious outlook from the investment bank regarding the pharmaceutical company's future perfo", "url": "https://www.marketscreener.com/news/morgan-stanley-downgrades-vertex-pharmaceuticals-to-equalweight-from-overweight-adjusts-pt-to-15-f-ce7f51dbd08bf020", "source_name": "marketscreener.com", "published_at": "2026-07-21T09:39:19", "published_display": "21 Jul 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Stock Trades Below Fair Value After Deal Plans", "summary": "Vertex Pharmaceuticals (VRTX) stock is currently trading below its estimated intrinsic value, according to a Discounted Cash Flow (DCF) model, despite a mixed picture from broader valuation checks and an upcoming $10 billion acquisition of Crinetics Pharmaceuticals. While the DCF", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-pharmaceuticals-vrtx-stock-trades-below-fair-value-af", "source_name": "Simply Wall Street", "published_at": "2026-07-21T01:09:00", "published_display": "21 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today", "summary": "Vertex Pharmaceuticals (VRTX) shares dropped by 1.06% to $480.50, underperforming the broader S&P 500, Dow, and Nasdaq markets. Despite this daily dip, the drugmaker has seen a 7.53% appreciation over the past month, outperforming its sector and the S&P 500. Investors are now loo", "url": "https://finance.yahoo.com/markets/stocks/articles/why-vertex-pharmaceuticals-vrtx-dipped-220006350.html", "source_name": "Market source", "published_at": "2026-07-20T21:38:55", "published_display": "20 Jul 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors", "summary": "Shares of Vertex Pharmaceuticals Inc. (VRTX) fell 1.06% on Monday, closing at $480.50. This underperformance occurred during a generally poor trading session where the S&P 500 Index declined by 0.19% and the Dow Jones Industrial Average dropped by 0.59%. This marks the second con", "url": "https://www.marketwatch.com/data-news/vertex-pharmaceuticals-inc-stock-underperforms-monday-when-compared-to-competitors-dbeedc00-cf7aec63ddb5", "source_name": "MarketWatch", "published_at": "2026-07-20T16:37:00", "published_display": "20 Jul 2026 16:37", "sentiment": "negative", "sentiment_pct": 27, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharma stock trades near highs as cystic fibrosis portfolio drives double digit revenue growt", "summary": "Vertex Pharmaceuticals (Vertex Pharma) stock is trading near highs due to robust revenue and profit growth driven by its cystic fibrosis (CF) portfolio. The company reported double-digit revenue increases and strong operating margins in its latest quarter, primarily from its CF t", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/vertex-pharma-stock-trades-near-highs-as-cystic-fibrosis-portfolio-drives/69813959", "source_name": "ad-hoc-news.de", "published_at": "2026-07-20T14:14:44", "published_display": "20 Jul 2026 14:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating", "summary": "Goldman Sachs has increased its price target for Vertex Pharmaceuticals to $652 from $641. The firm has concurrently maintained a \"Buy\" rating on the stock. This adjustment reflects Goldman Sachs' continued positive outlook on Vertex Pharmaceuticals.", "url": "https://www.marketscreener.com/news/goldman-sachs-adjusts-price-target-on-vertex-pharmaceuticals-to-652-from-641-maintains-buy-rating-ce7f51dbdb88f52c", "source_name": "www.marketscreener.com", "published_at": "2026-07-20T12:03:00", "published_display": "20 Jul 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex\u2019s IgA nephropathy drug derisked after Novartis, Vera approvals", "summary": "Vertex Pharmaceuticals' IgA nephropathy drug, povetacicept, is gaining momentum following recent FDA approvals for competing therapies from Novartis (Fabhalta) and Vera Therapeutics (Trutakna). Analysts believe these approvals will help educate the market and create a positive en", "url": "https://www.biospace.com/drug-development/vertexs-iga-nephropathy-drug-derisked-after-novartis-vera-approvals", "source_name": "BioSpace", "published_at": "2026-07-20T11:31:10", "published_display": "20 Jul 2026 11:31", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exploring High Growth Tech Stocks In The US For July 2026", "summary": "This article identifies top-performing high-growth tech stocks in the US for July 2026, amidst a market that has seen a 17% increase over the past year. It highlights companies like Travere Therapeutics, Madrigal Pharmaceuticals, and Cloudflare, detailing their operational focus,", "url": "https://simplywall.st/stocks/us/software/nyse-net/cloudflare/news/exploring-high-growth-tech-stocks-in-the-us-for-july-2026", "source_name": "Simply Wall Street", "published_at": "2026-07-20T10:41:07", "published_display": "20 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Stock Analysis: A Healthcare Giant with 14% Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPMmVxbEVMV2R1N1lRaHRuMDZYcnczcFdHc183ME1GUGpzd041ektydEpyaF93NDBqMGV3VlR0dzBBd3puVlpMenEtWWRmTTUyTWJGNDhJaVItQjB2LVB2alJFcUpCUXBTUFVyMzhUdlJ1WHBKRGVmcml0QnMtbVI2LXBoeTkwMXhTYXg4X1R4ZTFVTE12U0NxUnJVNlZHMmtLeC14aDh1eFFTOW5WWUpENGFqSDBjc0hOUFpHbmgtYzdhdV9EMXh0U1RZY0w3UERqN2JJ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-20T09:22:21+00:00", "published_display": "20 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How FDA\u2019s Pediatric Expansion of Casgevy at Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/fda-pediatric-expansion-casgevy-vertex-090930514.html", "source_name": "Simply Wall St.", "published_at": "2026-07-20T09:09:30+00:00", "published_display": "20 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals (CRNX) Proxy filing Summary", "summary": "Vertex Pharmaceuticals is set to acquire Crinetics Pharmaceuticals for approximately $10 billion ($8.8 billion net of cash), paying $85 per share in cash. This acquisition will bring PALSONIFY and atumelnant into Vertex's portfolio, with an expected combined peak annual revenue p", "url": "https://quartr.com/events/crinetics-pharmaceuticals-inc-crnx-proxy-filing_FkTiKVDo", "source_name": "Quartr", "published_at": "2026-07-20T09:41:34", "published_display": "20 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2", "summary": "Vertex Pharmaceuticals' gene therapy, exagamglogene autotemcel (Casgevy), has received expanded FDA approval to treat children as young as 2 years old with sickle cell disease or transfusion-dependent thalassemia. This approval provides new options for a pediatric group with limi", "url": "https://sg.finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-wins-fda-050717227.html", "source_name": "Market source", "published_at": "2026-07-20T05:07:21", "published_display": "20 Jul 2026 05:07", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching", "summary": "Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals for $10 billion to diversify its portfolio beyond its dominant cystic fibrosis drug market. The acquisition introduces Palsonify for acromegaly and pipeline candidates like atumelnant for congenital adrenal hyperp", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VRTX/pressreleases/3357249/vertex-pharmaceuticals-just-made-a-10-billion-acquisition-worth-watching/", "source_name": "The Globe and Mail", "published_at": "2026-07-19T22:08:56", "published_display": "19 Jul 2026 22:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Latigo preps IPO to fund non-opioid pain drug rival to Vertex\u2019s Journax", "summary": "Latigo Biotherapeutics plans an IPO to fund its non-opioid pain drug pipeline, including late-stage studies for LTG-001, an oral small-molecule Nav1.8 inhibitor. The company aims to compete with Vertex Pharmaceuticals' Journax, highlighting potential advantages in efficacy and ad", "url": "https://www.fiercebiotech.com/biotech/latigo-preps-ipo-fund-non-opioid-pain-drug-rival-vertexs-journax", "source_name": "Fierce Biotech", "published_at": "2026-07-19T14:07:00", "published_display": "19 Jul 2026 14:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?", "summary": "Penguin Solutions (PENG), Arista Networks (ANET), and Biocryst Pharmaceuticals (BCRX) all reached 52-week highs due to positive market sentiment and various catalysts. PENG benefited from increased analyst price targets driven by AI demand, ANET saw optimism for its cloud network", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-peng-anet-bcrx-shares-surge-to-52-week-highs/cZmokfgR7VS", "source_name": "Stocktwits", "published_at": "2026-07-18T15:40:03", "published_display": "18 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Arrowhead Pharmaceuticals (ARWR) Undervalued Or Is Its Pipeline Promise Already Priced In?", "summary": "Arrowhead Pharmaceuticals (ARWR) has seen recent stock volatility, with a 4.1% gain in the past day but an 8.3% drop over the last month, yet a strong 1-year return. Analysts view the stock as undervalued with a fair value of $89.08 against its current $74.30, driven by its promi", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/is-arrowhead-pharmaceuticals-arwr-undervalued-or-is-its-pipe", "source_name": "Simply Wall Street", "published_at": "2026-07-18T11:41:14", "published_display": "18 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Pediatric Casgevy Expansion and Canadian ALYFTREK Talks Change Vertex Pharmaceuticals' (VRTX) Narrative?", "summary": "U.S. regulators recently expanded approval of Vertex Pharmaceuticals' gene-editing therapy Casgevy for pediatric patients as young as 2 years old. Concurrently, Canada's pan-Canadian Pharmaceutical Alliance has initiated discussions for public reimbursement of Vertex's cystic fib", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/will-pediatric-casgevy-expansion-and-canadian-alyftrek-talks", "source_name": "Simply Wall Street", "published_at": "2026-07-18T03:47:39", "published_display": "18 Jul 2026 03:47", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Catalyst Pharmaceuticals (CPRX) Keep Looking Fairly Valued Now?", "summary": "Catalyst Pharmaceuticals stock has seen a significant 4.6x return over the past five years, yet its current valuation appears to be roughly in line with its fundamentals rather than being clearly cheap or overvalued. The company's P/E ratio of 17.4x is close to its estimated fair", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/can-catalyst-pharmaceuticals-cprx-keep-looking-fairly-valued", "source_name": "Simply Wall Street", "published_at": "2026-07-18T01:39:28", "published_display": "18 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monteverde investigates Element Solutions, Crinetics, and AstroNova sales", "summary": "Monteverde & Associates PC is investigating the proposed sale of Element Solutions Inc to Solstice Advanced Materials Inc for potential undervaluation and process adequacy. The firm is also scrutinizing the acquisitions of Crinetics Pharmaceuticals by Vertex Pharmaceuticals and A", "url": "https://scanx.trade/stock-market-news/companies/brodsky-smith-probes-four-mergers-over-potential-board-breaches/44910462", "source_name": "scanx.trade", "published_at": "2026-07-17T22:40:14", "published_display": "17 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains", "summary": "Shares of Vertex Pharmaceuticals Inc. (VRTX) rose 1.88% on Thursday, closing at $486.03. Despite this gain, the stock underperformed the broader market, with the S&P 500 Index falling 0.51% and the Dow Jones Industrial Average dropping 0.20%. This marks the second consecutive day", "url": "https://www.marketwatch.com/data-news/vertex-pharmaceuticals-inc-stock-underperforms-thursday-when-compared-to-competitors-despite-daily-gains-19a02af6-ea4f441256e3", "source_name": "MarketWatch", "published_at": "2026-07-16T16:36:00", "published_display": "16 Jul 2026 16:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOSDV4a01ZcnR5VndFbmVYc0t5clpyeTFZRzk1cG5hdDV2VEFyMjJRQkN6cGlKNWEyWjhwb2F5SVhpU2NYMjYxZnFUZGhWSW1JM2JyQ1YwT2dNTmFpVzlaWXlpRDRuQzlqVExlVzZtWC1DSVJXUDhSUFMyaVdVTXRNcy1Kd3QtNHdoNWhobXh5WVNYc3hpWDY4RmZfaTlleURIYUJyVkhfVV9KZ1VJZjFCTmc3YVM?oc=5", "source_name": "Market source", "published_at": "2026-07-16T13:00:03+00:00", "published_display": "16 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex (VRTX) Is Buying Crinetics For $10 Billion To Enter Adrenal Disease", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T12:51:43+00:00", "published_display": "15 Jul 2026 12:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vertex Pharmaceuticals (VRTX) A Bargain On Its Expanded CASGEVY Approval?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-14T01:02:21+00:00", "published_display": "14 Jul 2026 01:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex (VRTX) Stock May Be 36% Undervalued Following Its $10b Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNTk9HVDlSOUNLT1UtdHJneGNsa0JNaURYMFBZSDFTMGJlV19vb2NlUzcwTzFUbHIxMWhhdUhqSUs0b2prdUdTUTdGZ3hUQkt4Y09hMC1DMHVGMENIX1E4MVFMUjVSUllMOVJQRUtQdTM1ejZJNldGVkhaRjRsQVR4dWRodGJkM09xNzk2WmVrZ3h3ZXc?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex to buy Crinetics for $10 billion in rare-diseases push", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOX3N1NDFzcDNMSmVSODY1SEJGRm51Sl96QmtwWV9zMHA3RUZTRVlDenhJaG01alZQSU5KZUNWV2NFMFp6c0U5Xy1aZFZ2UXVmNWFGNk1HR1NMcGpJWHVpQjVtQWV2Z0FqMldWWHFwMlA2cHh1eDBtT19sem9BZ1ljblQta09WbWdBcjFzX3JVY2h2WlFsQ1VZ?oc=5", "source_name": "Reuters", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech (VRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPeUVTekQtYjFqODVQTUpmWnpTSlBZT3lEWmhDVjhFZEc2dDctNjZXZ0MySENpa01tQS1CLVgtNTB6cGRWNWIyME9BOGhpRGlDYWF2bWYxRHlnbEtmN3FuZUlVT2c5NVhqZlNjSUlVTWxvYUFCX29xUU4wemRLYkhnOFhnOFhBVmJvYVk5Q1VfaW5KLWN0bElGRG9fdmlXZ1VpNjRqR3NTaWlqQVRCOHdLRkUzdTlLblNPOENJ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOYUJCRHpLdzhuNmcxVnZLVUVLSWc3U0JqNVpuOHNLbmMwZmE4NG1Yb2M3Xy1CMUk0T1hjM3VmeEpTV2xJMmVTX1BiMk5VOG93WS1TeG1fQ2NlYk44cHBfQzFTZ2U1UERQSHlYU2lDeG1SQzNMOVJyazRvSDdVZ0JuMUtMbGdSU2xVXzBuRjdDN2dwaUd5Y1pXdVQwZ3h2alFHb0k3ZE9CVUM?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Stock After Strong Multi\u2011Year Run Is The Price Still Reasonable", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNVW9halB2RDE0V056SmV5NEd0Wl95ekI0eWM3QzVsckpLQ2RMWkF3SWRMSUFmMlViUHBObGVobXhwYW5CWU42WG5NUG45WHhDNGEzcHlheG1hM1lZWkpTOUs3UFFmUHdDOUw2V2tEV0N4YnlMY0d0cmswalo4WnZzTWlVZGd6ZmdyeW5WSXZJRFplSFkyRnREQnlJaVN4MFA3WS1uWU55blg?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Pediatric CASGEVY Data Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPNzJydi1RUXhvaVExQVVJWnhpYjEyb3NOVHJheExOYmsyLU5famxjRnRWdS1TSDJLWjZNUmtEa3RLNkZxaGVtYWNPSmFLSFJnNktJWDVHSk9DVFlmVVdLLWRmWHdiR19LZXpWZm9MWlU4VkVOOGp0QktVX3ZmdWtiZ25BSS05SzVqaEtacm9fSGI4bzcyMVN0RTNIWWFCaTA?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQY2F4dS1iZUJuTE1VNlVHQ1paVHg1U2VRUG5vcTZFdmFSdXB0Z0RQdVlkUXdxNzhYaGIzOVNhVWctVnJpUG1ZZFNydFkwUGo4Si1UdmtSaFNXb1RuQnNFdU1vekFEU3pGYVhwUnlvY01zdmJ6dXZrZ1Bia3ZDRHI4NGRCN1ZudnRWMkVYMzhleWp5OHpmdjJOdkRhVDJKYW9VMXE1dDV6dVhJQzR4aXI4?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQRWxFWWN4YWJiVXFtSzNneEtya1lidllZZmNGU3o3UUZMYU9nQUs1aEhsU1Vtc3I0ejVrLUladllOb2dGOS1WdUEwa3poZW42M0dsOHI0dVdpVUMxZW5tTTY3UWR3NEdNLUxUcEpVTVdtOVRtMDJudHZWQVFrNTBHRU9JSlB5WEJjUUZFRHZtU29CUVc1d1lnaWFGakRvdVRmMmZXWU1STlNOaXp4M1FmR1JoTlFQdVdfbWZFLVBsODM0ZVNVbF9sUjgzQkhscWRMQ2QwanU2UVhEazNOQmp6Y1VlYW0?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vertex Pharmaceuticals (VRTX) Offering An Opportunity After Recent Share Price Consolidation?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPcWMwYWZZaUg0UXcyV2UzR2RLeWJQYVZLWmJBakdUSDJQWWh3aUZaR3BpbVAzR1c2eDRmSzBoR0FJQjlfNVhYZjdmMTNxUm81OXJwaGhza1lYRm1OVXZHMDd1LUUwSDBzNzQzREwyWDAtenRZQVRBR1ZsT1FXbXhxWmxXWHU5SDZ1SlNTdFpBUXJNclVGSXBRMUpJc0lvRFNNemw2TnJ1aVlUYk01VHhFVThEaw?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vertex Pharmaceuticals (VRTX) Offering Opportunity After Recent Pipeline Headlines And DCF Valuation Gap", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPS0tESHdtOGhOSUhoZ3VTUUtOSXY0S3hLNzdNYmZMcmpMSTJVQkNpZDk2RzJDTEJJckdoNFZkR29zVGI3Vmh5OFV5cU5QNV80MFc1cjhyTlhKcFB2UG9MbkRoR2xZamR1NkNBQmhsRFRDYkQ1U21jLWpoMWE3bmxxT3BOY05vdjhWWmF0UXNGdjEyZE9TcjJYTlpfMnJOa2sxalJPT21rYWQ2d1JwZ0ZDa3pR?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals Stock Analysis: 1991 IPO Growth and 2026 Outlook - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPWDdRcmJnTUNiVGhhT0JTbEFuUzBQMm1JMmdoeFMxdld2TzM2LU8zZ2U4TWY5R0NRV2ZhX3dOT0pOS1JxekZwSERNZ1B2cDNkSFBNQUtBVVdhZVd0VHkxa1dpQlo0WTVNbXh5VXBWal9jOUdjZDVOQXg1N1UwdGN5LW14Q2YxLTZxR2xlVFA2SGpvOHRVWjlpNm5VTEZHZw?oc=5", "source_name": "IndexBox", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Profitability Return Tests Bullish Narratives Ahead Of Q1 2026 Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNRWFOTVJScjVfeFpiVTZmc2hTeXlYcGZrcTQzOVJ4Zm56Q3R0TUZNekFxT2ctOG90ZEJVRng5OVFaZ2JFQmNaaXBLazVPZTNaNDUxS0JhdEotYXlYMTR5aC1ocFo4REoxeVBkOUU1bEF3Q2tuSkxvYUh0aUxwSWh0ZlFfdkcwMHlNNUNxRGE0dVMzd1lfRC14TFppTzNaU3BtWk03Tl9hZ1Q1VEVt?oc=5", "source_name": "Business Wire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNbVlsb21NeHAzaFNyd2hzWmpjT3FkXzc1STMxN1pXelBvT0NqOEk3bnVybk1pUU4tTTZBc3M5eDdhaHNvUGp2MHZRNVc1S043NTVQc19kak5naTFENW5IMDhJYTlqZWdhRm1KMmhVbkFtVjh6bGc5dWhVVkR2UEZ6TENsZWFrNngyOHA4RjdHSW5JQjh4S3lXcjQ5UDhXZ0dWeW5UWHJtN3QyR1FHdU1WMWZFdGllZHVUQ2JtVGpoZmZXN0dQX0tsYXlETTREX2xLQ2hxTS1GREZkY1BfdEhlVFZ3YVJYOEItZmVkUm0xOVg?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vertex Pharmaceuticals Stock Looks Undervalued in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNWTUyZHZlVTI5dzItanJQSzJuOG15WjgyYWhfeGM0d2Q0S0FjRG9MYWdYaTZrbndwUG95T3hCVklReU5hQnlTc3VoWF9BM1h5WUhoendEeVdXaGxnc2Zpc0pEd0lwWVM3bFFMS0ROSE8yT0d0UHYxbV9vNzk1Y05mc2FfNy16Q1l2aWZzOQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPNWgxZmFPcUY5cHVqUjNNZ2pHVDE5Y0FJdnZBYmxLQlBKZnlGMC10UExaNUdzc0U1cWQxbmVKa1gzekFIazRWN3RsTTFKTGU0bURmV0dSbFVvVllDQS1mNnprR3lGQUxEQnNLR1FPWWhVdDZOVE9fRWZ4THNNQzdoUnk3ajg4amROUE9oUXBzWDFRUjg5N3c5ZzZ4S1NoeEkyNFY1OWVkQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQR3pDcWtZWjd1c1dwOTlpY0cwZUJkYWJCLVBlS0o0Y0ctOE5ENUh5b2dicHhSdGxmR19XblF0UzgtQkVaOTM1ZnFGcl85bS1DMGYtRzI5bTZwMVByeWs5YmVYcVR5elM4cjVHVmQ3aHpHWlRScUFKRWxtUVl3c3lhcFpndWt5MlVJY0xpdUpiRkNsUk84U3kyVHZLT2tPT3F5am40bE9YWFA?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals: Label Expansions For ALYFTREK & TRIKAFTA Plus Strong Demand (VRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPUG5ldEEyRWNlMlBnYTQyU0NlOHJScURVaWh2QzlncFdHRk1mQnlJRmZWUXNBa1EyVldJNXNCc3RxUVdzWXQ2eGllVnRVOG5PUHFhZm8tZUhEWmotYU9TX0lKYmJGd3ZuVTdoaGZWRmVVNXJPME5JYk1qR19od2JmY1NnZzM1aDFJNERPd01EUkt0YTB2YUt1YnpHT1lkZ21uZVhYd0laZDZlelpQbGI0bi1KSmFFU1JHSzg5NA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 80, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPdXIxTVd1ZHVTWmF3Tk55OHVsWW1aa204VXlzNkZuQWpfaGJkRjhlRncxRkZUb2ctYlJLV1hiY0QxYlFzMW9OS1A1WjlzaDhrclNGZUtXZ1gyRVNaTDRkUi1PcjBnVTBiVnpFaGdQWVBDRjh6b2FNZVNHcndESkNydFByQWVVTE9yU2RoUnZMSTFVdGdNakt0TlpoNXg5SnRDaWZSMUprbw?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves midday: Rivian, Hims & Hers, BioNTech, Vertex Pharmaceuticals & more", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxORWx1NTliZE5Gbm9JQTc5eWNBTDdjUWI3UEZtenJzM3g4aHJfVDF3cEtQNkdFQUpXQ2pWNW9qTkkxVFVjaVJPS0ZkbkptSmFrT2ZDQlktRE5UZG8ycGRpSl9nZ1JtY19fY1BTeDBGbXliS1RWVVdfUVNFaXpLVjdrT2s2dW5JNi1ZcjVSQ3lfMnVnekQzWE03dHZLbW9uQ1hX?oc=5", "source_name": "CNBC", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals Stock Pops 5% On Successful Late Stage Kidney Disease Drug Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxON3huRVNtLUZSdmZJR3AzZ1BJNlZfV3haaFBfRy1YMXFiYzV3NElYWlZyMHpqTXpSWTBXWGtfSHEzM0pkYWZpRWdqSENTeXA2RnhzZ3RGb1BuR1poVHV2Q3VyZ2lFN1ZZTC1MM0w3S2VQZ2tudllsYUpwQjBhcFMtbGhFT0tZaUtsSmF5QzY3RkNuMkFRZ3Z4dGEzVjVVU2tlNl9zNk41V2toQXlSQmlONnZOYmNRWWRY?oc=5", "source_name": "TIKR.com", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 107, "total_relevant": 56, "sentiment_summary": {"positive": 20, "negative": 2, "neutral": 34, "score": 56, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 18.25, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "deals", "label": "Deals and strategy", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 20, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 485.65, "latest_week": "2026-07-17", "one_week_move": 0.1, "four_week_move": 7.5, "twelve_week_move": 12.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.125288, "market_dynamics_buy_signal": false, "relative_strength": -1.188176, "fair_value_gap": 11.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 53.5374, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.1% over one week, +7.5% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 55, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 19}, {"label": "simplywall.st", "count": 6}, {"label": "Simply Wall Street", "count": 5}, {"label": "TradingView", "count": 2}, {"label": "MarketWatch", "count": 2}, {"label": "The Globe and Mail", "count": 2}, {"label": "Seeking Alpha", "count": 2}, {"label": "TIKR.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 12}, {"label": "Deals and strategy", "count": 5}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "6", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.1% over one week, +7.5% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?"}], "updated_at": "2026-07-22T09:42:20.856814+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}